Abstract 85P
Background
Characterization of the immune microenvironment is key. In tumors with wide presence of genomic alterations like non-small cell lung cancer (NSCLC) the evaluation of the immune profile can help to better select treatment options. In this study we explored the transcriptomic landscape of lung adenocarcinoma tumors (LUAD) with genomic alterations at SMARCA4.
Methods
Data from TCGA was downloaded to evaluate the expression of transcripts up or down regulated when deletions or disruptive mutations of SMARCA4 were present in LUAD. Median values were used and genes with fold change (FC) > than 2.5 were selected. Gene set enrichment analysis was performed with Enricher. TIMER platform was employed to investigate the association with immune cell populations.
Results
Of the 507 evaluated patients, disruptive mutations were present in 43 and gene deletions in 5. Molecular/biological functions enriched within the upregulated genes in tumors with SMACA4 deletions included: ncRNA 3'-end processing (GO:0043628) or ketosteroid monooxygenase activity (GO:0047086), among others; involving representative genes like CT45A10; SAGE1; CT45A3; CT45A5; CT45A1, AKR1C1; AKR1C2, CBR1 or CBR3. In tumors with no deletion the most represented molecular/biological functions included the antigen processing and presentation of lipid antigen via MHC class Ib (GO:0048003) with relevant genes as: CD1E; CD1C; CD1B; CD1A; CX3CR1; P2RY12, among others. Presence of CD1A, CD1B, CD1C, CD1E in tumors with no SMARCA4 genomic alterations strongly associated with the presence of dendritic cells (DC) (Corr Rho 0.41, 0.48, 0.44 and 0.45, respectively) and dendritic resting cells (DRC) (Corr Rho 0.75, 0.70, 0.71 and 0.72, respectively). A direct comparison between SMARC4 deletions and DC and DRC, showed a clear negative correlation (Corr Rho -0.5, -4,3, respectively). Similar findings were observed with SMARC4 mutations (DC Corr -0.69, DRC Corr -0.91).
Conclusions
SMARCA4 deletions in LUAD tumors associated with loss of antigen presenting genes including CD1E; CD1C; CD1B; CD1A that are present in myeloid dendritic cells. We hypothesized that loss of antigen presentation functions can be present in LUAD with genomic alterations of SMARCA4.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
45P - Therapeutic potential of ISM8207: A novel QPCTL inhibitor, in triple-negative breast cancer and B-cell non-Hodgkin lymphoma
Presenter: Sujata Rao
Session: Poster session 09
46P - Effect of coadministration of antioxidant chlorophyllin with docetaxel on invasion and metastasis in triple-negative breast cancer in vivo/in vitro
Presenter: Ayse Burus
Session: Poster session 09
47P - An ozone delivery system by cisplatin prodrug self-assembling micelles combining microwave to sensitizing immune checkpoint inhibitor in triple-negative breast cancer
Presenter: Dan Zheng
Session: Poster session 09
48P - Non-steroid anti-inflammatory treatment enhances the efficacy of modulated electro hyperthermia on triple-negative breast cancer and melanoma cancer models in vivo
Presenter: Nino Giunashvili
Session: Poster session 09
49P - Circulating miRNA signatures to predict recurrence in patients with pathological complete response of triple-negative breast cancer
Presenter: Ana Julia de Freitas
Session: Poster session 09
50P - Application and mechanism of tarloxotinib in HER2-positive breast cancer
Presenter: Xinyi Shao
Session: Poster session 09
51P - Nanoengineered sonosensitive platelets for synergistically augmented sonodynamic breast tumour therapy by glutamine deprivation and cascading thrombosis
Presenter: Liqiang Zhou
Session: Poster session 09
53P - Treatment of cancer cells based on circulating tumor cell’s expression profile using off-label drugs
Presenter: Panagiotis Apostolou
Session: Poster session 09
54P - Enhanced oxidative phosphorylation of metastasis-initiating cells facilitates esophageal tumor cell seeding in lymph nodes
Presenter: Shanshan Li
Session: Poster session 09
55P - Transcriptional profiles of engineered T cells stimulated with different receptor structures and co-stimulatory domains
Presenter: Ungue Shin
Session: Poster session 09